Regional infrastructure tied to inappropriate breast, prostate cancer imaging
the ONA take:
Danil Makarov, MD, MHS, of the New York University School of Medicine and fellow researchers user SEER-Medicare data to identify patients with low-risk prostate or breast cancer.
While these two cancers affect different patient populations and therefore should not share an association in imaging, the researchers found a correlation between regional rates, leading them to believe that regional behaviors share common determinants.
They identified 9,2119 men with prostate cancer and 30,398 women with breast cancer in 84 hospital referral regions, with rates of inappropriate imaging found to be 44.4 percent and 41.8 percent, respectively.
Inappropriate prostate cancer imaging rates were associated with those of breast cancer rates at the hospital referral region level. This meant that a man with low-risk prostate cancer had a higher chance of undergoing inappropriate imaging if he lived in a hospital referral region with higher inappropriate breast cancer imaging levels.
“Our findings suggest that practice patterns may be a function of local propensities for health care utilization,” the authors stated. “This is a novel finding with great relevance to cancer policy.”
Regional infrastructure could contribute to inappropriate imaging in patients at risk for prostate and breast cancer.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|